Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules

H. Guo, M. Gao, Y. Lu, J. Liang, P. L. Lorenzi, S. Bai, D. H. Hawke, J. Li, T. Dogruluk, K. L. Scott, E. Jonasch, Gordon Mills, Z. Ding

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Aberrant AKT activation is prevalent across multiple human cancer lineages providing an important new target for therapy. Twenty-two independent phosphorylation sites have been identified on specific AKT isoforms likely contributing to differential isoform regulation. However, the mechanisms regulating phosphorylation of individual AKT isoform molecules have not been elucidated because of the lack of robust approaches able to assess phosphorylation of multiple sites on a single AKT molecule. Using a nanofluidic proteomic immunoassay (NIA), consisting of isoelectric focusing followed by sensitive chemiluminescence detection, we demonstrate that under basal and ligand-induced conditions that the pattern of phosphorylation events is markedly different between AKT1 and AKT2. Indeed, there are at least 12 AKT1 peaks and at least 5 AKT2 peaks consistent with complex combinations of phosphorylation of different sites on individual AKT molecules. Following insulin stimulation, AKT1 was phosphorylated at Thr308 in the T-loop and Ser473 in the hydrophobic domain. In contrast, AKT2 was only phosphorylated at the equivalent sites (Thr309 and Ser474) at low levels. Further, Thr308 and Ser473 phosphorylation occurred predominantly on the same AKT1 molecules, whereas Thr309 and Ser474 were phosphorylated primarily on different AKT2 molecules. Although basal AKT2 phosphorylation was sensitive to inhibition of phosphatidylinositol 3-kinase (PI3K), basal AKT1 phosphorylation was essentially resistant. PI3K inhibition decreased pThr451 on AKT2 but not pThr450 on AKT1. Thus, NIA technology provides an ability to characterize coordinate phosphorylation of individual AKT molecules providing important information about AKT isoform-specific phosphorylation, which is required for optimal development and implementation of drugs targeting aberrant AKT activation.

Original languageEnglish (US)
Pages (from-to)3463-3472
Number of pages10
JournalOncogene
Volume33
Issue number26
DOIs
StatePublished - Jun 26 2014
Externally publishedYes

Fingerprint

Phosphorylation
Protein Isoforms
Phosphatidylinositol 3-Kinase
Immunoassay
Proteomics
Isoelectric Focusing
Drug Delivery Systems
Luminescence
Insulin
Ligands
Technology
Neoplasms

Keywords

  • AKT
  • NIA
  • phosphorylation

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Guo, H., Gao, M., Lu, Y., Liang, J., Lorenzi, P. L., Bai, S., ... Ding, Z. (2014). Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene, 33(26), 3463-3472. https://doi.org/10.1038/onc.2013.301

Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. / Guo, H.; Gao, M.; Lu, Y.; Liang, J.; Lorenzi, P. L.; Bai, S.; Hawke, D. H.; Li, J.; Dogruluk, T.; Scott, K. L.; Jonasch, E.; Mills, Gordon; Ding, Z.

In: Oncogene, Vol. 33, No. 26, 26.06.2014, p. 3463-3472.

Research output: Contribution to journalArticle

Guo, H, Gao, M, Lu, Y, Liang, J, Lorenzi, PL, Bai, S, Hawke, DH, Li, J, Dogruluk, T, Scott, KL, Jonasch, E, Mills, G & Ding, Z 2014, 'Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules', Oncogene, vol. 33, no. 26, pp. 3463-3472. https://doi.org/10.1038/onc.2013.301
Guo H, Gao M, Lu Y, Liang J, Lorenzi PL, Bai S et al. Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. Oncogene. 2014 Jun 26;33(26):3463-3472. https://doi.org/10.1038/onc.2013.301
Guo, H. ; Gao, M. ; Lu, Y. ; Liang, J. ; Lorenzi, P. L. ; Bai, S. ; Hawke, D. H. ; Li, J. ; Dogruluk, T. ; Scott, K. L. ; Jonasch, E. ; Mills, Gordon ; Ding, Z. / Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules. In: Oncogene. 2014 ; Vol. 33, No. 26. pp. 3463-3472.
@article{37f8243b025b422ea021a6ee98fdb01f,
title = "Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules",
abstract = "Aberrant AKT activation is prevalent across multiple human cancer lineages providing an important new target for therapy. Twenty-two independent phosphorylation sites have been identified on specific AKT isoforms likely contributing to differential isoform regulation. However, the mechanisms regulating phosphorylation of individual AKT isoform molecules have not been elucidated because of the lack of robust approaches able to assess phosphorylation of multiple sites on a single AKT molecule. Using a nanofluidic proteomic immunoassay (NIA), consisting of isoelectric focusing followed by sensitive chemiluminescence detection, we demonstrate that under basal and ligand-induced conditions that the pattern of phosphorylation events is markedly different between AKT1 and AKT2. Indeed, there are at least 12 AKT1 peaks and at least 5 AKT2 peaks consistent with complex combinations of phosphorylation of different sites on individual AKT molecules. Following insulin stimulation, AKT1 was phosphorylated at Thr308 in the T-loop and Ser473 in the hydrophobic domain. In contrast, AKT2 was only phosphorylated at the equivalent sites (Thr309 and Ser474) at low levels. Further, Thr308 and Ser473 phosphorylation occurred predominantly on the same AKT1 molecules, whereas Thr309 and Ser474 were phosphorylated primarily on different AKT2 molecules. Although basal AKT2 phosphorylation was sensitive to inhibition of phosphatidylinositol 3-kinase (PI3K), basal AKT1 phosphorylation was essentially resistant. PI3K inhibition decreased pThr451 on AKT2 but not pThr450 on AKT1. Thus, NIA technology provides an ability to characterize coordinate phosphorylation of individual AKT molecules providing important information about AKT isoform-specific phosphorylation, which is required for optimal development and implementation of drugs targeting aberrant AKT activation.",
keywords = "AKT, NIA, phosphorylation",
author = "H. Guo and M. Gao and Y. Lu and J. Liang and Lorenzi, {P. L.} and S. Bai and Hawke, {D. H.} and J. Li and T. Dogruluk and Scott, {K. L.} and E. Jonasch and Gordon Mills and Z. Ding",
year = "2014",
month = "6",
day = "26",
doi = "10.1038/onc.2013.301",
language = "English (US)",
volume = "33",
pages = "3463--3472",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "26",

}

TY - JOUR

T1 - Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules

AU - Guo, H.

AU - Gao, M.

AU - Lu, Y.

AU - Liang, J.

AU - Lorenzi, P. L.

AU - Bai, S.

AU - Hawke, D. H.

AU - Li, J.

AU - Dogruluk, T.

AU - Scott, K. L.

AU - Jonasch, E.

AU - Mills, Gordon

AU - Ding, Z.

PY - 2014/6/26

Y1 - 2014/6/26

N2 - Aberrant AKT activation is prevalent across multiple human cancer lineages providing an important new target for therapy. Twenty-two independent phosphorylation sites have been identified on specific AKT isoforms likely contributing to differential isoform regulation. However, the mechanisms regulating phosphorylation of individual AKT isoform molecules have not been elucidated because of the lack of robust approaches able to assess phosphorylation of multiple sites on a single AKT molecule. Using a nanofluidic proteomic immunoassay (NIA), consisting of isoelectric focusing followed by sensitive chemiluminescence detection, we demonstrate that under basal and ligand-induced conditions that the pattern of phosphorylation events is markedly different between AKT1 and AKT2. Indeed, there are at least 12 AKT1 peaks and at least 5 AKT2 peaks consistent with complex combinations of phosphorylation of different sites on individual AKT molecules. Following insulin stimulation, AKT1 was phosphorylated at Thr308 in the T-loop and Ser473 in the hydrophobic domain. In contrast, AKT2 was only phosphorylated at the equivalent sites (Thr309 and Ser474) at low levels. Further, Thr308 and Ser473 phosphorylation occurred predominantly on the same AKT1 molecules, whereas Thr309 and Ser474 were phosphorylated primarily on different AKT2 molecules. Although basal AKT2 phosphorylation was sensitive to inhibition of phosphatidylinositol 3-kinase (PI3K), basal AKT1 phosphorylation was essentially resistant. PI3K inhibition decreased pThr451 on AKT2 but not pThr450 on AKT1. Thus, NIA technology provides an ability to characterize coordinate phosphorylation of individual AKT molecules providing important information about AKT isoform-specific phosphorylation, which is required for optimal development and implementation of drugs targeting aberrant AKT activation.

AB - Aberrant AKT activation is prevalent across multiple human cancer lineages providing an important new target for therapy. Twenty-two independent phosphorylation sites have been identified on specific AKT isoforms likely contributing to differential isoform regulation. However, the mechanisms regulating phosphorylation of individual AKT isoform molecules have not been elucidated because of the lack of robust approaches able to assess phosphorylation of multiple sites on a single AKT molecule. Using a nanofluidic proteomic immunoassay (NIA), consisting of isoelectric focusing followed by sensitive chemiluminescence detection, we demonstrate that under basal and ligand-induced conditions that the pattern of phosphorylation events is markedly different between AKT1 and AKT2. Indeed, there are at least 12 AKT1 peaks and at least 5 AKT2 peaks consistent with complex combinations of phosphorylation of different sites on individual AKT molecules. Following insulin stimulation, AKT1 was phosphorylated at Thr308 in the T-loop and Ser473 in the hydrophobic domain. In contrast, AKT2 was only phosphorylated at the equivalent sites (Thr309 and Ser474) at low levels. Further, Thr308 and Ser473 phosphorylation occurred predominantly on the same AKT1 molecules, whereas Thr309 and Ser474 were phosphorylated primarily on different AKT2 molecules. Although basal AKT2 phosphorylation was sensitive to inhibition of phosphatidylinositol 3-kinase (PI3K), basal AKT1 phosphorylation was essentially resistant. PI3K inhibition decreased pThr451 on AKT2 but not pThr450 on AKT1. Thus, NIA technology provides an ability to characterize coordinate phosphorylation of individual AKT molecules providing important information about AKT isoform-specific phosphorylation, which is required for optimal development and implementation of drugs targeting aberrant AKT activation.

KW - AKT

KW - NIA

KW - phosphorylation

UR - http://www.scopus.com/inward/record.url?scp=84903583096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903583096&partnerID=8YFLogxK

U2 - 10.1038/onc.2013.301

DO - 10.1038/onc.2013.301

M3 - Article

VL - 33

SP - 3463

EP - 3472

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 26

ER -